

Table S1 Studies characteristics

Study	Type of study	Language	Patients enrolled (N), green/TURP	Mean age (range), years, green/TURP	IPSS after 3 months, green/TURP	IPSS after 6 months, green/TURP	IPSS after 12 months, green/TURP	Mean preoperative PSA serum (ng/mL), green/TURP	IIEF5, green/TURP	Mean Vres after 3 months (mL), green/TURP	Mean Vres after 6 months (mL), green/TURP	Mean Vres after 12 months (mL), green/TURP	Mean Qmax after 3 months (mL/s), green/TURP	Mean Qmax after 6 months (mL/s), green/TURP	Mean Qmax after 12 months (mL/s), green/TURP	Mean operative time (min), green/TURP	Mean catheterization time (days), green/TURP	Mean postoperative hospital stay (days), green/TURP	Postoperative complications (Clavien-Dindo), green/TURP	Follow-up periodization (months)
Bachmann, 2018	Prospective randomized trial	English	10/10	NS	NS	NS	6.0±5.2 (NS)/4.2±4.5 (NS)	3.8±2.6/4.3±2.6	NS	NS	NS	34.6±39.5/30.5±33	NS	NS	25.8±8.2/25.2±9.7	NS	NS	NS	NS	6, 12, and 24
Horasanli, 2008	Prospective randomized trial	English	39/37	69.2±7.1 (59–78)/68.6±6.7 (58–76)	11.2±7.6 (4–24)/6.1±5.4 (2–14)	13.1±5.8 (4–26)/6.4±7.9 (2–16)	NS	5.2±4.5 (2.8–20)/4.7±3.8 (2.2–19)	19±5.2 (4–28)/21±6.8 (6–30)	69.1±38.8 (20–140)/15.7±14.9 (5–60)	78.9±62.1 (20–210)/22.9±18.7 (10–85)	NS	14.1±8.7 (10–24)/21.3±12.8 (16–34)	13.3±7.9 (10–22)/20.7±11.3 (15–32)	NS	87±18.3 (60–110)/51±17.2 (43–95)	1.7±0.8 (1–3)/3.9±1.2 (2–7)	2±0.7 (1–3)/4.8±1.2 (1–6)	19 patients grade I, 12 grade II and 9 grade III/22 patients grade I, 9 grade II, and 3 grade III	3 and 6
Mu, 2016	Prospective non–randomized trial	English	42/39	70.45±5.52/71.15±6.33	8.24±3.9*/7.10±2.8*	6.18±2.95*/4.55±4*	4.98±2.65*/3.47±2.31*	5.55±2.72/6.01±3.43	NS	20.7±25.7*/16.2±12.1*	18.6±32.5*/13±26.1*	16.5±22.3*/10.2±18.6*	21.2±4.4*/23±7.5*	22±4*/25.1±6.8*	22.4±4.2*/25.8±6*	89.60±20.18/83.59± 12.96	2.29±0.8*/4.58±1.15*	3.60±1.78/5.82±1.05	2 patients grade I, 11 grade II and 2 grade III/2 patients grade I, 5 grade II, and 1 grade III	1, 3, 6 and 12
Sarica, 2007	Prospective randomized trial	English	28/32	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	99.6±19.1/68.7±17.2	1.6±0.8/4.1±1.1	1.1±0.4/2.8±1.2	NS	6 and 12
Tasci, 2008	Prospective non–randomized trial	English	40/41	71.8±5.9/70.1±5.4	6.5±0.2/6.5±0.2	4.3±0.1/4.4±0.1	3.5±0.1 (NS)/3.6±0.12 (NS)	5.1±1.3/5.4±1.1	NS	26.2±12.6/24.3±9.3	13.4±2.9/16.6±7.4	12.1±5.2/11.3±4.2	18.4±0.2/16.9±2.2	19.6±0.2/19.8±2.5	20±0.2/19±2.3	126.2±17.4/77.9±8.3	1.16±0.8*/3.1±1.15*	1.7±0.96*/3.8±1.15*	9 patients grade I, 3 grade II and 9 grade III/9 patients grade I, 4 grade II, and 8 grade III	1, 3, 6, 12 and 24

The continuous variables were represented by mean ± SD (range). *, according to the general principles of dealing with missing data from Cochrane, we imputed the standart deviation based on the mean from the others studies. BMI, body mass index; NS, non-specified; SD, standard deviation; IPSS, International Prostate Symptom Score; Qmax, maximum urinary flow rate; Vres, postvoid residual volume.